Načítá se...
Targeting wild-type KRAS amplified gastroesophageal cancer through combined MEK and SHP2
The role of KRAS, when activated through canonical mutations, has been well established in cancer(1). Here we explore a secondary means of KRAS activation in cancer, focal high-level amplification of the KRAS gene in the absence of coding mutations. These amplifications occur most commonly in esopha...
Uloženo v:
Vydáno v: | Nat Med |
---|---|
Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Médium: | Artigo |
Jazyk: | Inglês |
Vydáno: |
2018
|
Témata: | |
On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6039276/ https://ncbi.nlm.nih.gov/pubmed/29808010 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41591-018-0022-x |
Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|